Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral
doses of rigosertib, a new investigational (unapproved) anti-cancer drug. The objective of
the study is to determine the highest dose of drug that can be given safely. The study will
start by testing a low dose. If this dose is safe, then, higher and higher doses will be
tested as long as the previous lower dose was safe. Safety will be determined by looking for
any side effects or unusual laboratory values. It is important to know the highest safe dose
so that additional studies can be done. The drug will be given in the form of capsules twice
or three times a day for 21 consecutive days of 21-day cycles.